Dr. Reddy Laboratories and GAIL India Ltd Share Q2 Result

No image 5paisa Research Team

Last Updated: 8th August 2022 - 06:55 pm

Listen icon

Dr. Reddy's Laboratories - Q2 Results


Dr. Reddy's Laboratories Ltd reported stellar numbers for the September 2021 quarter as its top line revenues grew by 17.7% at Rs.4,987 crore. Even on a quarter on quarter basis, the revenues were higher by 17.15%, showing even short term traction in the top line. Here is a gist of the key financials of Dr. Reddy Laboratories.

 

Rs in Crore

Sep-21

Sep-20

YOY

Jun-21

QOQ

Total Income (Rs cr)

₹ 5,763.20

₹ 4,896.70

17.70%

₹ 4,919.40

17.15%

Net Profit (Rs cr)

₹ 992.00

₹ 762.00

30.18%

₹ 571.00

73.73%

Diluted EPS (Rs)

₹ 59.65

₹ 45.83

 

₹ 34.34

 

Net Margins

17.21%

15.56%

 

11.61%

 


What were the triggers for the revenue growth. Let us look at specific verticals. Revenues from the pharma ingredients and the API segment were lower by 2.6% yoy at Rs.999 crore and that was due to supply chain constraints in the business. However, revenues from global generics were up 19% at Rs.4,743 crore and accounted for a bulk of the top line.

Net profits for the Sep-21 quarter were higher by 30.2% at Rs.992 crore. This was on the back of a spurt in the gross margins by 600 bps to 53.4%. Reddy Labs spent Rs.446 crore on  R&D which is 7.7% of sales, and well above the peer group median. EBITDA margins at 27% improved by 600 bps quarter on quarter. India and EM markets showed best growth.

Reddy Labs had a comfortable net debt to equity ratio of 0.015X. Free cash flows stood at Rs.83 crore, which can considered small for a company of that size and scale. Net margins for Reddy Labs at 17.21% was surely better than 15.56% in the Sep-20 year ago quarter and it was sharply better than NPM of 11.6% in Jun-21 quarter.
 

GAIL India Ltd - Q2 Results


India’s largest gas transportation company, GAIL India, reported 67.39% growth in total revenues for the Sep-21 quarter on consolidated basis at Rs21,782cr. The revenues were higher by 73% on a sequential basis compared to Rs17,589cr revenues in the Jun-21 quarter. There was a volume boost and also a price boost linked to crude oil prices.

 

Rs in Crore

Sep-21

Sep-20

YOY

Jun-21

QOQ

Total Income (Rs cr)

₹ 21,782

₹ 13,012

67.39%

₹ 17,589

23.84%

Net Profit (Rs cr)

₹ 2,883

₹ 1,112

159.34%

₹ 2,138

34.88%

Diluted EPS (Rs)

₹ 6.49

₹ 2.47

 

₹ 4.81

 

Net Margins

13.24%

8.54%

 

12.15%

 

 

In terms of verticals of GAIL, the major boost to revenues came from the natural gas marketing vertical which was up by 71% at Rs21,011cr. Two other verticals viz.  natural gas transmission and LPG transmission was almost flat on YoY basis. However petchem, liquid hydrocarbons and the CGD business saw good growth in revenues on YoY basis.

Net profits were up 159.34% for the Sep-21 quarter at Rs.2,883 crore. Profits were also higher by 35% on a quarter to quarter basis. The big boost to EBIT came from natural gas marketing which went from an EBIT loss of Rs-335 crore to an EBIT profit of Rs.1,029 crore. That actually triggered the boost to the overall profits to GAIL.

The EBIT contributions of CGD, liquid hydrocarbons and petchem also showed growth like in the case of the top line. However, this was on a much lower base. Net profit margins at 13.24% was substantially superior to 8.54% in the Sep-20 quarter and was also better than the net profit margins of 12.15% in Jun-21 quarter.

How do you rate this article?
Characters remaining (1500)

FREE Trading & Demat Account
+91
''
By proceeding, you agree T&C*
Mobile No. belongs to
hero_form

Indian Stock Market Related Articles

Upcoming IPOs of Adani Group

by 5paisa Research Team 20th Sep 2024

Tata Group's Upcoming IPOs

by 5paisa Research Team 17th Sep 2024

Upcoming IPOs in September 2024

by 5paisa Research Team 17th Sep 2024

Best Silver Stocks 2024

by 5paisa Research Team 13th Sep 2024

Best Gold Stock to Invest before 2024 Ends!

by 5paisa Research Team 12th Sep 2024

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Want to Use 5paisa
Trading App?